Kangchen Pharmaceuticals: KC1036 combined with PD-1/PD-L1 antibodies for the treatment of advanced solid tumors received a clinical trial notification letter.

Kangchen Pharmaceuticals announced that recently, the company received the approval notification for the clinical trial of "KC1036 combined with PD-1/PD-L1 for the treatment of recurrent or metastatic advanced solid tumors" issued by the National Medical Products Administration. KC1036 is a first-class innovative drug independently developed by the company, and the company owns the global intellectual property rights to this product. KC1036 achieves its anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL. KC1036 has strong VEGFR vascular targeting, inhibiting tumor cell growth; by inhibiting AXL, it can improve the host's anti-tumor immune response, thereby avoiding tumor immune escape. Currently, clinical studies of KC1036 are being conducted for multiple indications including digestive system tumors, thymus tumors, and pediatric rhabdomyosarcoma. As of now, more than 350 subjects have been enrolled in the KC1036 clinical studies, and the current clinical research results show outstanding anti-tumor activity and safety.